Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer

被引:265
|
作者
Gao, N
Zhang, Z
Jiang, BH
Shi, XL
机构
[1] Chinese Acad Sci, Inst Nutr Sci, Shanghai, Peoples R China
[2] W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA
[3] W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA
关键词
D O I
10.1016/j.bbrc.2003.09.132
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer is one of the most common cancers among men. Recent studies demonstrated that PI3K signaling is an important intracellular mediator which is involved in multiple cellular functions including proliferation, differentiation, anti-apoptosis, tumorigenesis, and angiogenesis. In the present study, we demonstrate that the inhibition of PI3K activity by LY294002, inhibited prostate cancer cell proliferation and induced the G(1) cell cycle arrest. This effect was accompanied by the decreased expression of G(1)-associated proteins including cyclin D1, CDK4, and Rb phosphorylation at Ser780, Ser795, and Ser807/811, whereas expression of CDK6 and beta-actin was not affected by LY294002. The expression of cyclin kinase inhibitor, p21(CIP1/WAF1) was induced by LY294002, while levels of p16(INK4) were decreased in the same experiment. The inhibition of PI3K activity also inhibited the phosphorylation and p70(S6K), but not MAPK. PI3K regulates cell cycle through AKT, mTOR to p70(S6K). The mTOR inhibitor rapamycin has similar inhibitory effects on G, cell cycle progression and expression of cyclin D1, CDK4, and Rb phosphorylation. These results suggest that PI3K mediates G(1) cell cycle progression and cyclin expression through the activation of AKT/mTOR/p70(S6K) signaling pathway in the prostate cancer cells. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:1124 / 1132
页数:9
相关论文
共 50 条
  • [1] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [2] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [3] Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer
    Wang, Shuaibin
    Zhang, Chao
    Xu, Zhifang
    Chen, Michael H.
    Yu, Haiyan
    Wang, Lizhong
    Liu, Runhua
    PROSTATE, 2023, 83 (01): : 97 - 108
  • [4] The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
    Matsuoka, Tasuku
    Yashiro, Masakazu
    CANCERS, 2014, 6 (03) : 1441 - 1463
  • [5] Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
    Chang, Lei
    Graham, Peter H.
    Ni, Jie
    Hao, Jingli
    Bucci, Joseph
    Cozzi, Paul J.
    Li, Yong
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (03) : 507 - 517
  • [6] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [7] PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
    Angel Guerrero-Zotano
    Ingrid A. Mayer
    Carlos L. Arteaga
    Cancer and Metastasis Reviews, 2016, 35 : 515 - 524
  • [8] PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
    Guerrero-Zotano, Angel
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    CANCER AND METASTASIS REVIEWS, 2016, 35 (04) : 515 - 524
  • [9] Ilicicolin C suppresses the progression of prostate cancer by inhibiting PI3K/AKT/mTOR pathway
    Gan, Xia
    Luo, Xiaowei
    Chen, Jingqin
    Fang, Wenxuan
    Nie, Mingyi
    Lu, Humu
    Liu, Yonghong
    Wang, Xueni
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2025, 480 (02) : 1089 - 1104
  • [10] PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression
    Fath, Mohsen Karami
    Masouleh, Ramtin Akhavan
    Afifi, Negin
    Loghmani, Shirin
    Tamimi, Parham
    Fazeli, Alireza
    Mousavian, Seyed Ali
    Falsafi, Mohammad Mehdi
    Barati, Ghasem
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 241